Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases
Britney N. Lizama, Jennifer Kahle, Susan M. Catalano, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6251-6251
Open Access | Times Cited: 25

Showing 25 citing articles:

The Human Ganglioside Interactome in Live Cells Revealed Using Clickable Photoaffinity Ganglioside Probes
Gao‐Lan Zhang, Mitchell J. Porter, Abduselam K. Awol, et al.
Journal of the American Chemical Society (2024) Vol. 146, Iss. 26, pp. 17801-17816
Closed Access | Times Cited: 8
Autophagy in dry AMD: A promising therapeutic strategy for retinal pigment epithelial cell damage
Zhao Zhang, Fengming Liang, Jun Chang, et al.
Experimental Eye Research (2024) Vol. 242, pp. 109889-109889
Closed Access | Times Cited: 6
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter
Kelsie M. LaBarbera, Yvette I. Sheline, Nicholas J. Izzo, et al.
Translational Neurodegeneration (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 16
The Sigma Receptors in Alzheimer’s Disease: New Potential Targets for Diagnosis and Therapy
Tao Wang, Hongmei Jia
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12025-12025
Open Access | Times Cited: 15
An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease
B.N. Lizama, H.A. North, Kiran Pandey, et al.
Neurobiology of Disease (2024) Vol. 199, pp. 106575-106575
Open Access | Times Cited: 5
TMEM97 governs partial epithelial-mesenchymal transition of retinal pigment epithelial cells via the CTNND2-ADAM10 axis
Jing Li, Yosuke Nagasaka, Hongtao Shen, et al.
Molecular Therapy — Nucleic Acids (2025) Vol. 36, Iss. 1, pp. 102460-102460
Open Access
Commercial Route Development of Sigma-2 Receptor Modulator, CT1812 Leveraging Photoflow, and HTS Technologies
Steven A. Weissman, Christopher J. Kassl, Siead Zegar, et al.
Organic Process Research & Development (2025)
Closed Access
Sigma-2 receptor modulator CT1812 alters key pathways and rescues retinal pigment epithelium (RPE) functional deficits associated with dry age-related macular degeneration (AMD)
Britney N. Lizama, Eloise Keeling, Eun-Ah Cho, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials
Lorenzo Moccia, Francesca Bardi, Maria Benedetta Anesini, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 540-540
Open Access
Untargeted Lipidomics Analysis to Discover Lipid Profiles and Biomarkers of Rabbit Acne Model and Reveal Action Mechanism of Isotretinoin
Liang Wu, Yunxia Zhu, Shengcai Zhu, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 4003-4016
Open Access | Times Cited: 3
Transmembrane protein TMEM97 and epigenetic reader BAHCC1 constitute an axis that supports pro-inflammatory cytokine expression
Jing Li, Hongtao Shen, Lian‐Wang Guo
Cellular Signalling (2024) Vol. 116, pp. 111069-111069
Closed Access | Times Cited: 2
Structure-Affinity relationships of novel σ2R/TMEM97 ligands
Grant D. Walby, Qi Gu, Hongfen Yang, et al.
Bioorganic Chemistry (2024) Vol. 145, pp. 107191-107191
Closed Access | Times Cited: 2
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease
Britney N. Lizama, Claire Williams, Hilary A. North, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 2
Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities
Na Ye, Qi Wang, Yue Li, et al.
Medicinal Research Reviews (2024)
Closed Access | Times Cited: 2
Discovery of WLB-89462, a New Drug-like and Highly Selective σ2 Receptor Ligand with Neuroprotective Properties
Ute Christmann, José Luis Dı́az, Rosalía Pascual, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12499-12519
Closed Access | Times Cited: 5
Sigma Receptors: Novel Regulators of Iron/Heme Homeostasis and Ferroptosis
Nhi Nguyen, Valeria Jaramillo‐Martinez, Marilyn Mathew, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14672-14672
Open Access | Times Cited: 5
A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer’s Disease
Everard G.B. Vijverberg, Willem de Haan, E. Scheijbeler, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Closed Access | Times Cited: 1
Development of selective sigma-1 receptor ligands with antiallodynic activity: a focus on piperidine and piperazine scaffolds
Giuseppe Cosentino, Maria Dichiara, Francesca Alessandra Ambrosio, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117037-117037
Closed Access | Times Cited: 1
Emerging Oral Pharmaceuticals for Dry Age-Related Macular Degeneration: Mechanism of Action, Current Clinical Status, and Future Directions
Charles DeBoer, Ditte K. Rasmussen, Joel A. Franco, et al.
Ophthalmic surgery, lasers & imaging retina (2024) Vol. 55, Iss. 9, pp. 528-534
Closed Access
2-(Piperidin-3-yl)phthalimides reduce classical markers of cellular inflammation in LPS-challenged RAW 264.7 cells and also demonstrate potentially relevant sigma and serotonin receptor affinity in membrane preparations
Michael T. Scerba, David Tweedie, Nigel H. Greig
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 110, pp. 129885-129885
Open Access
Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist
Guramrit Kaur, Zahid Ahmad Dar, Ankit Bajpai, et al.
Clinical Therapeutics (2024)
Closed Access
Multitarget-Directed Ligands Hitting Serotonin Receptors: A Medicinal Chemistry Survey
Imane Ghafir El Idrissi, A. Di Santo, Enza Lacivita, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 9, pp. 1238-1238
Open Access
Neuroprotective Effect of Sigma-2 Modulator CT2074 in a Mouse Model of Ocular Hypertension
N. T. Donkor, Charles Kiehlbauch, Nathaniel Pappenhagen, et al.
Experimental Eye Research (2024) Vol. 249, pp. 110143-110143
Open Access
Microarray-Based Methodology for Lipid Profiling, Enzymatic Activity, And Binding Assays in Printed Lipid Raft Membranes from Astrocytes and Neurons
Laura Sánchez-Sánchez, Roberto Fernández, Egoitz Astigarraga, et al.
Analytical Chemistry (2024)
Closed Access
A review of the mechanisms involved in the neuroprotection and neurotoxicity of Iboga alkaloids
Boukandou Mounanga Marlaine Michele, Aboughe Angone Sophie
Pharmacological Research - Natural Products (2023) Vol. 1, pp. 100006-100006
Closed Access
Page 1

Scroll to top